GW Pharma (GWPH) (GWP) Gains; Epidiolex Treatment Effect in Children
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
April 22, 2015 6:15 PM EDTConference Call Today at 6:30 p.m. ET
New data issued in a poster presentation at the American Academy of Neurology annual meeting on 137 patients, representing increased patient numbers over previous disclosures Promising signals of efficacy with median 54% reduction in seizures after 12 weeks treatment and maintenance of clinical effect at 24 weeks Epidiolex was well tolerated and 90% of patients remained on treatment Data on Lennox-Gastaut syndrome (LGS) patients presented for first time Additional body of data in patients with diagnoses other than Dravet syndrome GW advancing plans to commence clinical... More
